EUVIMEDEUVIMED entdecken
Evaluationsstudie

Refining Risk Stratification for Oesophageal Varices in HCV ‐Related Cirrhosis: A Comprehensive Analysis of the Albumin Platelet Product and Elastography Biomarkers

Maha Elsabaawy iD, Madiha Naguib, Mai Magdy, Ahmed Shaban, Essam Zayed

Journal of Viral Hepatitis · 2026-03 · 33 (3)

DOI: 10.1111/jvh.70146 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 12.02.2026. Verfasst von Maha Elsabaawy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Menoufia, Egypt. Hauptthemen laut MEDLINE: Esophageal and Gastric Varices, Liver Cirrhosis, Elasticity Imaging Techniques, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The albumin platelet product (APP) has recently been explored as a non‐invasive marker of liver fibrosis, but its potential to predict portal hypertension and oesophageal varices (OVs) remains under‐evaluated. This study aimed to assess the diagnostic accuracy of APP in predicting and grading OVs in cirrhotic patients and to compare its performance with established serum indices and elastography‐based measures. A total of 372 patients with HCV‐related liver cirrhosis underwent upper endoscopy for OV assessment. APP was calculated and evaluated alongside liver stiffness (LS), spleen stiffness (SS), aspartate aminotransferase‐to‐platelet ratio index (APRI) and fibrosis‐4 (FIB‐4). In the derivation cohort, APP demonstrated an AUROC of 0.80 (95% CI: 0.75–0.86) for detecting OVs, comparable to LS (0.82; 95% CI: 0.76–0.88) and superior to SS (0.78; 95% CI: 0.71–0.84), FIB‐4 (0.68; 95% CI: 0.61–0.74) and APRI (0.66; 95% CI: 0.60–0.72). In the validation cohort, APP maintained a robust performance (AUROC 0.79; 95% CI: 0.73–0.85), confirming reproducibility. For high‐risk (large) varices, APP achieved an AUROC of 0.87 (95% CI: 0.82–0.93), outperforming LS (0.83; 95% CI: 0.77–0.89) and SS (0.85; 95% CI: 0.79–0.91). Accordingly, the APP demonstrates superior accuracy over liver and spleen stiffness in predicting oesophageal varices among patients with HCV‐related cirrhosis, offering a cost‐effective, non‐invasive alternative within this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal and Gastric VaricesLiver CirrhosisElasticity Imaging TechniquesBiomarkersHepatitis C, ChronicBlood PlateletsHumansFemaleMaleMiddle AgedRisk AssessmentAgedAdultSerum AlbuminSpleenLiver

Stichwörter der Autor:innen

APPBaveno VIIalbumin platelet productelastographyoesophageal varicespredictors

Substanzen

BiomarkersSerum Albumin

Autor:innen und Institutionen

  • Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Menoufia, Egypt.

ORCID-Profile: Maha Elsabaawy

Zitieren

APA

Elsabaawy, M., Naguib, M., Magdy, M., Shaban, A., & Zayed, E. (2026). Refining Risk Stratification for Oesophageal Varices in HCV ‐Related Cirrhosis: A Comprehensive Analysis of the Albumin Platelet Product and Elastography Biomarkers. Journal of Viral Hepatitis, 33(3). https://doi.org/10.1111/jvh.70146

Vancouver

Elsabaawy M, Naguib M, Magdy M, Shaban A, Zayed E. Refining Risk Stratification for Oesophageal Varices in HCV ‐Related Cirrhosis: A Comprehensive Analysis of the Albumin Platelet Product and Elastography Biomarkers. Journal of Viral Hepatitis. 2026;33(3). doi:10.1111/jvh.70146

BibTeX
@article{Elsabaawy2026,
  author = {Elsabaawy, Maha and Naguib, Madiha and Magdy, Mai and Shaban, Ahmed and Zayed, Essam},
  title = {Refining Risk Stratification for Oesophageal Varices in HCV ‐Related Cirrhosis: A Comprehensive Analysis of the Albumin Platelet Product and Elastography Biomarkers},
  journal = {Journal of Viral Hepatitis},
  year = {2026},
  volume = {33},
  number = {3},
  doi = {10.1111/jvh.70146}
}
Kostenlos starten →